✦ LIBER ✦

PCN40 COST OF MANAGING ADVERSE EVENTS IN THE TREATMENT OF FIRST LINE METASTASIC RENAL CELL CARCINOMA: BEVACIZUMAB + INTERFERON ALPHA-2A COMPARED WITH SUNITINIB IN SPAIN

✍ Scribed by V Calderero; X García-Muro; J Puente; JM Trigo; AJ Castro; V Martín-Escudero; M Yébenes; MA Casado

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

7141 Costs of adverse events management

✍ Puente, J.; Calderero, V.; García-Muro, X.; Trigo, J.M.; Castro, A.J.; Martin-Es 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

PCN42 COSTS OF MANAGING ADVERSE EVENTS O

✍ F Carlos; J Ramirez; A Aguirre 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB

Costs of managing adverse events in the

✍ Mickisch, G; Gore, M; Escudier, B; Procopio, G; Walzer, S; Nuijten, M 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 356 KB

Regarding: ‘Costs of managing adverse ev

✍ Porta, C 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 97 KB

Reply: Costs of managing adverse events

✍ Mickisch, G H J; Escudier, B; Walzer, S; Nuijten, M 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 159 KB

Comment on ‘Costs of managing adverse ev

✍ Charbonneau, C; Sandin, R 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 155 KB